Table 1. Clinico-pathologic characteristics of analyzed samples.
| HealthyMucosa | Inflamed Mucosa | HPP | SSP/A | TSA | TbA | Ca | Met | |||
| Total Patients (n = 95) | 23 | 4 | 12 | 14 | 5 | 8 | 20 | 9 | ||
| Total samples (n = 126) | 24 | 9 | 23 | 20 | 8 | 13 | 20 | 9 | ||
| Age | 69.5±17.7 | 23±21.9 | 60±17.5 | 59±15.3 | 78±9.8 | 64±5.5 | 68.5±10,1 | 60±7,7 | ||
| Gender (M:F) | 13∶10 | 3∶1 | 7∶5 | 5∶9 | 1∶4 | 5∶3 | 12∶8 | 4∶2 | ||
| Location (R:L) | 13∶11 | 3∶6 | 11∶12 | 13∶7 | 2∶6 | 4∶9 | 6∶14 | – | ||
| Size (mm) | <5 | – | – | 11 | 8 | 2 | 1 | – | – | |
| ≥5 | – | – | 12 | 12 | 6 | 12 | – | – | ||
| BRAF (c600) | n.t. | n.t. | 6 | 14 | .0 | 1 | 1 | 0 | ||
| KRAS (c12/13) | n.t. | n.t. | 8 | 3 | 4 | 4 | 10 | 2 | ||
| MSS | n.t. | n.t. | 23/23 | 20/20 | 8/8 | 13/13 | 17/20 | 9/9 | ||
| Grading | Well | – | – | – | – | – | – | 4 | ||
| Moderate | – | – | – | – | – | – | 10 | 6 | ||
| Poor | – | – | – | – | – | – | 6 | 3 | ||
| Stage | Dukes A | – | – | – | – | – | – | 3 | – | |
| Dukes B | – | – | – | – | – | – | 6 | – | ||
| Dukes C | – | – | – | – | – | – | 9 | – | ||
| Dukes D unknown | 0 | 9 | ||||||||
| 2 | ||||||||||
| Site | Liver | – | – | – | – | – | – | – | 6 | |
| Lung | – | – | – | – | – | – | – | 2 | ||
| Others | – | – | – | – | – | – | – | 1 | ||
Abbreviations: HPP: hyperplastic polyp; SSA/P: sessile serrated polyp/adenoma; TSA: traditional serrated adenoma; TbA: tubular adenoma; Ca: invasive colorectal carcinoma; Met: Metastasis; BRAF c600: B1 Rapidly accelerated fibrosarcoma codon 600 mutation; KRAS c12/13: Kirsten rat sarcoma codon 12 or 13 mutation.; n.t.: not tested; -: not applicable.